Group

Distribution by Scientific Domains
Distribution within Medical Sciences

Kinds of Group

  • abelian group
  • abo blood group
  • abundant group
  • ac group
  • acetyl group
  • acid group
  • active group
  • active treatment group
  • acupuncture group
  • acyl group
  • ad group
  • additional group
  • adhd group
  • adolescent group
  • adult group
  • advisory group
  • age group
  • age-matched control group
  • age-matched group
  • aged group
  • alcohol group
  • alcoholic group
  • aldehyde group
  • alendronate group
  • alfentanil group
  • alkoxy group
  • alkyl group
  • allyl group
  • alone group
  • american group
  • amide group
  • amine group
  • amino group
  • ammonium group
  • anesthesia group
  • animal group
  • another group
  • ap group
  • aromatic group
  • aryl group
  • as group
  • asd group
  • assessment group
  • asthma group
  • asymptomatic group
  • at-risk group
  • author group
  • b group
  • bacterial group
  • basal group
  • benign group
  • benzoyl group
  • benzyl group
  • bipolar group
  • block group
  • blocking group
  • blood group
  • bm group
  • boc group
  • bpd group
  • bridging group
  • business group
  • butyl group
  • c group
  • c space group
  • ca group
  • cabg group
  • cancer group
  • cancer study group
  • carbamate group
  • carbonyl group
  • carboxamide group
  • carboxy group
  • carboxyl group
  • carboxylic acid group
  • carboxylic group
  • carcinoma group
  • care group
  • case group
  • cd group
  • cell group
  • certain group
  • cf3 group
  • ch group
  • ch2 group
  • ch3 group
  • chemotherapy group
  • child group
  • children oncology group
  • client group
  • clinical group
  • cm group
  • cn group
  • co group
  • cohort group
  • collaborative group
  • combination group
  • combined group
  • common group
  • comorbid group
  • comparative group
  • comparator group
  • comparison group
  • compatibility group
  • complex group
  • con group
  • concentration group
  • consecutive group
  • consensus group
  • contact dermatitis research group
  • control group
  • conventional group
  • cooh group
  • cooperative group
  • cooperative oncology group
  • core group
  • cp group
  • cr group
  • crown group
  • cs group
  • csa group
  • ct group
  • cultural group
  • cyano group
  • daily group
  • day group
  • delivery group
  • demographic group
  • depressed group
  • dermatitis research group
  • diabetes group
  • diabetic group
  • diagnosis group
  • diagnosis-related group
  • diagnostic group
  • diet group
  • different group
  • different space group
  • directing group
  • disadvantaged group
  • discussion group
  • disease group
  • disorder group
  • distinct group
  • diverse group
  • dm group
  • dominant group
  • donor group
  • dosage group
  • dose group
  • dr group
  • drug group
  • ds group
  • e group
  • early group
  • early-onset group
  • eastern cooperative oncology group
  • elderly group
  • electron-withdrawing group
  • elite group
  • emerging group
  • end group
  • entire group
  • epoxy group
  • eradication group
  • ester group
  • et group
  • ethanol group
  • ether group
  • ethnic group
  • ethyl group
  • european group
  • exercise group
  • experimental group
  • expert group
  • exposed group
  • exposure group
  • f group
  • failure group
  • family group
  • female group
  • fentanyl group
  • fifth group
  • first group
  • flap group
  • fluoride group
  • focal group
  • focus group
  • former group
  • formyl group
  • fourth group
  • fracture group
  • free amino group
  • functional group
  • g group
  • gauge group
  • gel group
  • genetic group
  • german contact dermatitis research group
  • gh group
  • h group
  • ha group
  • haem group
  • hcc group
  • hd group
  • head group
  • health group
  • healthy control group
  • healthy group
  • heart group
  • heavier group
  • heme group
  • hepatitis group
  • heterogeneous group
  • hi group
  • high group
  • high risk group
  • high-dose group
  • high-risk group
  • historical comparison group
  • historical control group
  • historical group
  • homogeneous group
  • hp group
  • ht group
  • hydroxy group
  • hydroxyl group
  • hydroxymethyl group
  • hypertensive group
  • i group
  • ic group
  • ii group
  • im group
  • imidazole group
  • imino group
  • immigrant group
  • impairment group
  • implant group
  • important group
  • income group
  • independent group
  • index group
  • indigenous group
  • infant group
  • infection group
  • infliximab group
  • infusion group
  • initial group
  • injection group
  • injury group
  • interest group
  • intermediate group
  • international group
  • international study group
  • international working group
  • intervention group
  • invasive group
  • ir group
  • irradiated group
  • island group
  • italian group
  • ketamine group
  • keto group
  • key group
  • kg group
  • l group
  • lamivudine group
  • laparoscopic group
  • large group
  • larger group
  • largest group
  • last group
  • late group
  • late-onset group
  • latter group
  • lean group
  • leaving group
  • lidocaine group
  • lie group
  • linkage group
  • local group
  • low group
  • low-dose group
  • low-risk group
  • lr group
  • lt group
  • m group
  • main group
  • major group
  • male group
  • management group
  • matched comparison group
  • matched control group
  • matched group
  • medical group
  • methoxy group
  • methyl group
  • methylene group
  • mg group
  • mi group
  • microbial group
  • midazolam group
  • migraine group
  • mild group
  • minority group
  • misoprostol group
  • mite group
  • mixed group
  • model group
  • moderate group
  • monoclinic c space group
  • monoclinic space group
  • monophyletic group
  • monotherapy group
  • month group
  • mpa group
  • mtx group
  • multidisciplinary group
  • muscle group
  • n group
  • n-terminal amino group
  • nac group
  • natal group
  • natural group
  • negative control group
  • negative group
  • new group
  • nh group
  • nh2 group
  • nitro group
  • no2 group
  • node group
  • non-diabetic group
  • non-responder group
  • nontreated group
  • normal control group
  • normal group
  • novel group
  • o group
  • oa group
  • obese group
  • od group
  • oh group
  • oil group
  • olanzapine group
  • old group
  • older age group
  • older group
  • oldest age group
  • oncology group
  • one ethnic group
  • one group
  • one methyl group
  • one patient group
  • only group
  • onset group
  • opcab group
  • open group
  • original group
  • other group
  • ovx group
  • own group
  • oxide group
  • oxo group
  • p group
  • p21 space group
  • p21/n space group
  • pain group
  • parallel group
  • particular group
  • patient group
  • pd group
  • pediatric age group
  • pediatric group
  • peer group
  • pendant group
  • pendent group
  • periodontitis group
  • pes group
  • phenol group
  • phenolic group
  • phenolic hydroxyl group
  • phenyl group
  • phosphate group
  • phosphonate group
  • phosphoryl group
  • phylogenetic group
  • pioglitazone group
  • placebo group
  • placebo-treated group
  • plant group
  • point group
  • polar group
  • polar head group
  • polycomb group
  • population group
  • positive control group
  • positive group
  • pre-eclamptic group
  • pregnancy group
  • pregnant group
  • present group
  • prevention group
  • previous group
  • probiotic group
  • product group
  • professional group
  • prognosis group
  • prognostic group
  • propofol group
  • prospective group
  • prosthetic group
  • protecting group
  • protective group
  • psoriasis group
  • r group
  • ra group
  • racial group
  • radiation therapy oncology group
  • reactive group
  • recurrence group
  • recurrent group
  • reduction group
  • reference group
  • referent group
  • relate group
  • renormalization group
  • representative group
  • research group
  • respiratory group
  • responder group
  • response group
  • review group
  • risk group
  • rituximab group
  • ropivacaine group
  • rosiglitazone group
  • rt group
  • sa group
  • saline group
  • saline-treated control group
  • saline-treated group
  • same age group
  • same functional group
  • same group
  • same space group
  • sample group
  • sc group
  • schizophrenia group
  • se group
  • second control group
  • second group
  • select group
  • selected group
  • separate group
  • severe group
  • sevoflurane group
  • sf group
  • sh group
  • sham group
  • sham-operated group
  • shock group
  • side group
  • significant group
  • sildenafil group
  • similar group
  • single group
  • sister group
  • size group
  • small group
  • smaller group
  • smoking group
  • social group
  • social support group
  • socio-economic group
  • socioeconomic group
  • space group
  • spacer group
  • special group
  • special interest group
  • specialist group
  • species group
  • species-rich group
  • specific group
  • stage group
  • stakeholder group
  • standard group
  • statin group
  • stent group
  • steroid group
  • stimulation group
  • stress group
  • stroke group
  • studied group
  • study group
  • subject group
  • sucrose group
  • sulfhydryl group
  • sulfinyl group
  • sulfonyl group
  • supplemented group
  • support group
  • surgery group
  • surgical group
  • survival group
  • survivor group
  • symmetry group
  • syndrome group
  • tacrolimus group
  • target group
  • taxonomic group
  • teriparatide group
  • terminal group
  • terminal hydroxyl group
  • test group
  • tetragonal space group
  • therapy group
  • therapy oncology group
  • thiol group
  • third group
  • tip group
  • tooth group
  • total group
  • trained group
  • training group
  • trajectory group
  • treated group
  • treatment group
  • trial group
  • trifluoroacetyl group
  • trifluoromethyl group
  • trophic group
  • uc group
  • unexposed group
  • unique group
  • unselected group
  • untrained group
  • untreated control group
  • untreated group
  • urea group
  • us group
  • user group
  • v group
  • vaccine group
  • validation group
  • vegetative compatibility group
  • vehicle group
  • vehicle-treated group
  • ventilation group
  • ventral respiratory group
  • vinyl group
  • vitamin e group
  • vs. group
  • vulnerable group
  • wait-list control group
  • walking group
  • water group
  • weight group
  • well-defined group
  • western group
  • whole group
  • whole study group
  • work group
  • working group
  • writing group
  • year age group
  • year group
  • young group
  • younger age group
  • younger group
  • youngest age group
  • youngest group

  • Terms modified by Group

  • group a patient
  • group action
  • group activity
  • group affiliation
  • group allocation
  • group alone
  • group analysis
  • group antigen
  • group approach
  • group assignment
  • group b
  • group b patient
  • group b streptococcus
  • group b.
  • group b2
  • group behavior
  • group being
  • group boundary
  • group box
  • group box chromosomal protein
  • group c
  • group c.
  • group c2
  • group c2221
  • group care
  • group cbt
  • group change
  • group characteristic
  • group classification
  • group climate
  • group cohesion
  • group communication
  • group comparison
  • group composition
  • group comprising
  • group concentration
  • group consensus
  • group consisting
  • group content
  • group context
  • group contribution
  • group contribution method
  • group control
  • group counseling
  • group criterioN
  • group d
  • group data
  • group database
  • group decision
  • group decision-making
  • group decreased
  • group density
  • group design
  • group difference
  • group discussion
  • group diversity
  • group dynamics
  • group e
  • group education
  • group effect
  • group effectiveness
  • group effects
  • group element
  • group environment
  • group evaluation
  • group exercise
  • group experience
  • group f
  • group female
  • group formation
  • group g
  • group galaxy
  • group gene
  • group h
  • group home
  • group home range
  • group i
  • group i intron
  • group i metabotropic glutamate receptor
  • group i patient
  • group i.
  • group ia
  • group identification
  • group identity
  • group ii
  • group ii intron
  • group ii metabotropic glutamate receptor
  • group ii patient
  • group ii rat
  • group iia
  • group iii
  • group influence
  • group interaction
  • group interest
  • group intervention
  • group interview
  • group iv
  • group l
  • group lead
  • group leader
  • group level
  • group m
  • group male
  • group market
  • group mean
  • group meeting
  • group member
  • group membership
  • group metal
  • group method
  • group methodology
  • group methods
  • group migration
  • group movement
  • group n
  • group norm
  • group o
  • group only
  • group p
  • group p.
  • group p1
  • group p2
  • group p21
  • group p21212
  • group p212121
  • group p3121
  • group p41212
  • group paradigm
  • group participant
  • group participation
  • group patient
  • group pattern
  • group performance
  • group performance status
  • group phytoplasma
  • group politics
  • group power
  • group practice
  • group present
  • group process
  • group program
  • group programme
  • group project
  • group protein
  • group protocol
  • group psychoeducation
  • group psychotherapy
  • group r
  • group r3
  • group receiving
  • group relationship
  • group relationships
  • group report
  • group representation
  • group research
  • group response
  • group richness
  • group right
  • group sample
  • group score
  • group selection
  • group session
  • group setting
  • group showing
  • group shows
  • group size
  • group status
  • group strategy
  • group structure
  • group studies
  • group study
  • group subject
  • group success
  • group supervision
  • group support
  • group symmetry
  • group system
  • group technique
  • group testing
  • group theory
  • group therapy
  • group threat
  • group tolerance
  • group training
  • group transcript
  • group transfer
  • group transformation
  • group treatment
  • group treatment programme
  • group trial
  • group trials
  • group trials register
  • group used
  • group v
  • group validity
  • group value
  • group velocity
  • group vi
  • group vii
  • group vs.
  • group w
  • group woman
  • group work
  • group x

  • Selected Abstracts


    Impact of nutrition on outcome: A prospective randomized controlled trial in patients with head and neck cancer undergoing radiotherapy

    HEAD & NECK: JOURNAL FOR THE SCIENCES & SPECIALTIES OF THE HEAD AND NECK, Issue 8 2005
    Paula Ravasco MD
    Abstract Background. We aimed to determine the effect of dietary counseling or oral supplements on outcome for patients with cancer, specifically, nutritional outcome, morbidity, and quality of life (QOL), during and 3 months after radiotherapy. Methods. Seventy-five patients with head and neck cancer who were referred for radiotherapy (RT) were randomized to the following groups: group 1 (n = 25), patients who received dietary counseling with regular foods; group 2 (n = 25), patients who maintained usual diet plus supplements; and group 3 (n = 25), patients who maintained intake ad lib. Nutritional intake (determined by diet history) and status (determined by Ottery's Subjective Global Assessment), and QOL (determined by the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire version 3.0 [EORTC QLQ-C30]) were evaluated at baseline, at the end of RT, and at 3 months. Results. Energy intake after RT increased in both groups 1 and 2 (p , .05). Protein intake also increased in both groups 1 and 2 (p , .006). Both energy and protein intake decreased significantly in group 3 (p < .01). At 3 months, group 1 maintained intakes, whereas groups 2 and 3 returned to or below baseline levels. After RT, >90% of patients experienced RT toxicity; this was not significantly different between groups, with a trend for reduced symptomatology in group 1 versus group 2/group 3 (p < .07). At 3 months, the reduction of incidence/severity of grade 1+2 anorexia, nausea/vomiting, xerostomia, and dysgeusia was different: 90% of the patients improved in group 1 versus 67% in group 2 versus 51% in group 3 (p < .0001). After RT, QOL function scores improved (p < .003) proportionally with improved nutritional intake and status in group 1/group 2 (p < .05) and worsened in group 3 (p < .05); at 3 months, patients in group 1 maintained or improved overall QOL, whereas patients in groups 2 and 3 maintained or worsened overall QOL. Conclusions. During RT, nutritional interventions positively influenced outcomes, and counseling was of similar/higher benefit; in the medium term, only counseling exerted a significant impact on patient outcomes. © 2005 Wiley Periodicals, Inc. Head Neck27: XXX,XXX, 2005 [source]


    Effects of estrogen and androgen deprivation on the progression of non-alcoholic steatohepatitis (NASH) in male Sprague,Dawley rats

    HEPATOLOGY RESEARCH, Issue 9 2009
    Yanjun Mu
    Aim:, We studied the mechanisms of estrogen/androgen involvement in the induction of NASH by treating Sprague,Dawley (SD) rats fed with a normal or high fat (HF) diet by depriving them of endogenous estrogens/androgens. Methods:, Male adult SD rats (n = 10/group) on normal or HF diets were treated for 75 days either with tamoxifen (Tam) or flutamide (Flu) or Tam + Flu in order to induce NASH. We analyzed histopathologically the liver samples from the treated groups for NASH, checked the serum biochemical and lipid profile markers and finally analyzed the signal pathways underlying the molecular mechanisms for the induction process of NASH. Results:, Deprivation of endogenous estrogens and/or androgens (Tam or Flu or Tam + Flu) without the HF diet did not induce NASH. Tam or Tam + Flu induced NASH, compared to milder lesions without fibrosis in HF diet and Flu-treated liver. Serum alanine aminotransferase or lipid profile markers further proved the Tam, Flu or Tam + Flu effects on the induction of NASH in conjunction with a HF diet. Tam treatment predominantly downregulated the ER, and FAS and upregulated UCP2 and TNF-,. Conclusions:, Deprivation of endogenous estrogen/androgens in conjunction with a HF diet may induce NASH where the downregulated ER, and FAS, and upregulated UCP2 and TNF-, could be involved in their molecular pathomechanism pathways. These results could suggest the potential negative roles of estrogenic/androgenic depriving compounds in the induction of NASH, along with obesity. [source]


    Amylin and Bone Metabolism in Streptozotocin-Induced Diabetic Rats

    JOURNAL OF BONE AND MINERAL RESEARCH, Issue 5 2001
    Marie-Noėlle Horcajada-Molteni
    Abstract Amylin (AMY) is a 37 amino acid peptide cosecreted with insulin (INS) by pancreatic ,-cells and absent in type 1 diabetes, a condition frequently associated with osteopenia. AMY binds to calcitonin receptors, lowers plasma calcium concentration, inhibits osteoclast activity, and stimulates osteoblasts. In the present study, we examined the effects of AMY replacement on bone loss in a streptozotocin (STZ)-induced rodent model type 1 diabetes. Of 50 male Wistar rats studied, 40 were made diabetic with intraperitoneal STZ (50 mg/kg; plasma glucose concentrations >11 mM within 5 days). Ten nondiabetic control (CONT) rats received citrate buffer without STZ. Diabetic rats were divided into four groups (n = 10/group) and injected subcutaneously with rat AMY (45 mg/kg), INS (12 U/kg), both (same doses), or saline (STZ; diabetic controls) once per day. After 40 days of treatment and five 24-h periods of urine collection for deoxypyridinoline (DPD), the animals were killed, blood was sampled, and femurs were removed. The left femur was tested for mechanical resistance (three-point bending). The right femur was tested for total, diaphyseal (cortical bone), and metaphyseal (trabecular bone) bone densities using dual-energy X-ray absorptiometry (DXA). Bone was ashed to determine total bone mineral (calcium) content. None of the treatments had any significant effect on femoral length and diameter. Untreated diabetic rats (STZ; 145 ± 7N) had lower bone strength than did nondiabetic CONT (164 ± 38; p < 0.05). Total bone mineral density (BMD; g/cm2) was significantly lower in STZ (0. 2523 ± 0. 0076) than in CONT (0.2826 ± 0.0055), as were metaphyseal and diaphyseal densities. Diabetic rats treated with AMY, INS, or both had bone strengths and bone densities that were indistinguishable from those in nondiabetic CONT. Changes in bone mineral content paralleled those for total BMD (T-BMD). Plasma osteocalcin (OC) concentration, a marker for osteoblastic activity, was markedly lower in untreated diabetic rats (7. 6 ± 0. 9 ng/ml); p < 0. 05) than in nondiabetic CONT (29. 8 ± 1. 7; p < 0. 05) or than in AMY (20. 1 ± 0. 7; p < 0. 05). Urinary DPD excretion, a marker for bone resorption, was similar in untreated and AMY-treated diabetic rats (35.0 ± 3.1 vs. 35.1 ± 4.4 nmol/mmol creatinine), intermediate in rats treated with INS (49.9 ± 2.7), and normalized in diabetic rats treated with both agents (58.8 ± 8.9 vs. 63.2 ± 4.5 in CONT). Thus, in our STZ rat model of diabetic osteopenia, addition of AMY improved bone indices apparently by both inhibiting resorption and stimulating bone formation. [source]


    A Soybean Cultivar Lacking Lipoxygenase 2 and 3 Has Similar Calcium Bioavailability to a Commercial Variety Despite Higher Calcium Absorption Inhibitors

    JOURNAL OF FOOD SCIENCE, Issue 3 2008
    H.S.D. Martino
    ABSTRACT:, The aim of this study was to evaluate calcium bioavailability of a new soybean variety without 2 lipoxygenases with better taste and flavor than a commercial variety containing all 3 isozymes. Using the femur 45Ca uptake method, calcium absorption from a new Brazilian variety, UFV-116, was compared to a common Brazilian variety, OCEPAR 19. Male Sprague,Dawley growing rats weighing 150 to 170 g (10/group) received test meals of whole fat soy flour prepared from UFV-116 or OCEPAR-19 seeds labeled with 10 ,Ci of 45Ca. Femurs were removed after 48 h for determination of 45Ca uptake. Calcium fractional absorption was equivalent between the 2 varieties. The higher oxalate:calcium molar ratio and the higher content of oxalate and phytate (P < 0.05) found in the UFV-116 variety did not affect calcium absorption. Therefore, the new variety is a comparable source of high bioavailable calcium. [source]


    Prolonged antigen-exposure with carbohydrate particle based vaccination prevents allergic immune responses in sensitized mice

    ALLERGY, Issue 6 2009
    S. Thunberg
    Background:, Defined particles carrying tightly bound allergens at high density have been suggested as alternatives in allergy vaccination. Carbohydrate based particles (CBP), sized 2 ,m, provide a platform for covalent coupling of allergens. Objective:, To investigate the mechanisms of antigen presentation by CBP, as well as cellular and humoral responses after vaccination with the major cat allergen Fel d 1, covalently coupled to CBP. Methods:, Mice (n = 10/group) were subcutaneously vaccinated with CBP-rFel d 1, CBP or phosphate buffer saline (PBS) before sensitization with rFel d 1 and challenged with cat dander extract. Fluorescent and 75Se-radiolabeled tracking of allergens and particles were performed with flow cytometry and whole-body autoradiography. Humoral, cellular and regulatory immune responses were analyzed by ELISA and flow cytometry. Cytokines were measured in bronchoalveolar lavage fluid and splenocyte cultures. Results:, CBP-rFel d 1 prevented induction of airway inflammation and induced allergen-specific T-cell anergy. CBP-rFel d 1 also induced rapid IgM and IgG1-responses compared with soluble rFel d 1. Particles were phagocytosed by antigen-presenting cells and transported to draining lymph nodes and spleen. Moreover, antigen coupled to CBP remained longer at the injection site compared with alum. Conclusions:, Covalent coupling of rFel d 1 to CBP induces rapid antibody production, prevents induction of allergic immune responses and systemic allergen spreading. Thus, CBP comprise several attractive adjuvant features for use in allergy vaccination. Clinical Implications:, Prolonged allergen exposure through covalent coupling to particles suitable for phagocytosis, provides an adjuvant for safer and efficient allergy vaccination. [source]


    Prevention of diabetes: effect of mycophenolate mofetil and anti-CD25 on onset of diabetes in the DRBB rat

    PEDIATRIC DIABETES, Issue 6 2008
    Figen Ugrasbul
    Background:, Anti-CD25 and mycophenolate mofetil (MMF) treatment of patients with new-onset diabetes is currently being tested as one of the trials in TrialNet. We tested the effectiveness of MMF and anti-CD25 in preventing autoimmune diabetes in the diabetes-resistant biobreeding (DRBB) rat. Methods:, Autoimmune diabetes in the DRBB rat was induced with a Treg cell depletion regimen starting at 24,26 d of age. Treatment was started on the first day of the depletion regimen in the following groups: (i) control (vehicle); (ii) MMF 25 mg/kg/d intramuscularly daily for 8 wk; (iii) anti-CD25 0.8 mg/kg/d intraperitoneally 5 d/wk for 3 wk; and (iv) combination of MMF and anti-CD25. In a second set of experiments, treatments were started on day 5 of the depletion regimen (delayed treatment) with groups 1, 3, and 4. Rats that had diabetes-free survival for at least 30 d after the treatment was stopped underwent a second Treg depletion (redepletion). Results:, In each of the three treatment groups (n = 10/group), onset of diabetes was delayed or prevented in 20, 40 and 80% in groups 2, 3, and 4, respectively. After redepletion, diabetes-free survival was unchanged in group 2 and decreased to 10 and 30% in groups 3 and 4, respectively. With delayed treatment, groups 3 and 4 had 33 and 50% diabetes-free survival that decreased to 0 and 33% after redepletion. Summary:, MMF and anti-CD25 alone or in combination are effective in delaying and preventing diabetes in the DRBB rat especially if treatment is started before stimulation and expansion of the autoreactive T cells. [source]


    Chloroplast-derived vaccine antigens confer dual immunity against cholera and malaria by oral or injectable delivery

    PLANT BIOTECHNOLOGY JOURNAL, Issue 2 2010
    Abdoreza Davoodi-Semiromi
    Summary Cholera and malaria are major diseases causing high mortality. The only licensed cholera vaccine is expensive; immunity is lost in children within 3 years and adults are not fully protected. No vaccine is yet available for malaria. Therefore, in this study, the cholera toxin-B subunit (CTB) of Vibrio cholerae fused to malarial vaccine antigens apical membrane antigen-1 (AMA1) and merozoite surface protein-1 (MSP1) was expressed in lettuce and tobacco chloroplasts. Southern blot analysis confirmed homoplasmy and stable integration of transgenes. CTB-AMA1 and CTB-MSP1 fusion proteins accumulated up to 13.17% and 10.11% (total soluble protein, TSP) in tobacco and up to 7.3% and 6.1% (TSP) in lettuce, respectively. Nine groups of mice (n = 10/group) were immunized subcutaneously (SQV) or orally (ORV) with purified antigens or transplastomic tobacco leaves. Significant levels of antigen-specific antibody titres of immunized mice completely inhibited proliferation of the malarial parasite and cross-reacted with the native parasite proteins in immunoblots and immunofluorescence studies. Protection against cholera toxin challenge in both ORV (100%) and SQV (89%) mice correlated with CTB-specific titres of intestinal, serum IgA and IgG1 in ORV and only IgG1 in SQV mice, but no other immunoglobulin. Increasing numbers of interleukin-10+ T cell but not Foxp3+ regulatory T cells, suppression of interferon-, and absence of interleukin-17 were observed in protected mice, suggesting that immunity is conferred via the Tr1/Th2 immune response. Dual immunity against two major infectious diseases provided by chloroplast-derived vaccine antigens for long-term (>300 days, 50% of mouse life span) offers a realistic platform for low cost vaccines and insight into mucosal and systemic immunity. [source]


    Methylene blue attenuates lung injury after mesenteric artery clamping/unclamping

    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, Issue 6 2004
    A. A. Weinbroum
    Abstract Background, This controlled, experimental study was designed to assess the effects of intratracheal and intravenous methylene blue on reperfusion lung injury following superior mesenteric artery clamping/unclamping. Materials and methods, Superior mesenteric arteries of 144 anaesthetized adult male Wistar rats (n = 12/group) were clamped for 1 h. Ten minutes before unclamping, methylene blue or its vehicle was administered intratracheally or intravenously, followed by a 3 h-respiratory assessment and postexperimental assessment of survival. Results, Intravenous 3 and 9 mg kg,1 but not higher methylene blue doses, and intratracheal 6-mg kg,1 but not lower doses, significantly (P < 0·05) reduced the 100% increase in plateau pressure, 30% reduction in PO2/FiO2, fourfold augmented bronchoalveolar lavage-retrieved volume and the increased polymorphonuclear leukocytes/bronchoalveolar cells' ratio associated with unclamping of the superior mesenteric artery. Lung tissue polymorphonuclear leukocytes count, total xanthine oxidase activity and wet-to-dry-weight ratio were also normal in these dose-treated groups. These effective regimens were also associated with longer animal survival. Conclusions, Intratracheal methylene blue mitigates lung reperfusion injury following superior mesenteric artery clamping/unclamping at a similar magnitude as an intravenous regimen. This finding is a novel potential use of methylene blue in vivo. [source]


    Hypertrophied hearts: what of sevoflurane cardioprotection?

    ACTA ANAESTHESIOLOGICA SCANDINAVICA, Issue 4 2009
    J. R. LARSEN
    Background: Recent studies have demonstrated that inhalation anaesthetics, like sevoflurane, confer cardioprotection both experimentally and clinically. However, coexisting cardiac disease might diminish anaesthetic cardioprotection and could partly explain why the clinical results of cardioprotection with anaesthetics remain controversial , in contrast to solid experimental evidence. Concomitant left ventricular hypertrophy is found in some cardiac surgery patients and could change cardioprotection efficacy. Hypertrophy could potentially render the heart less susceptible to sevoflurane cardioprotection and more susceptible to ischaemic injury. We investigated whether hypertrophy blocks sevoflurane cardioprotection, and whether tolerance to ischaemia is altered by left ventricular hypertrophy, in an established experimental animal model of ischaemia,reperfusion. Methods: Anaesthetized juvenile pigs (n=7,12/group) were subjected to 45 min distal coronary artery balloon occlusion, followed by 120 min of reperfusion. Controls were given pentobarbital, while sevoflurane cardioprotection was achieved by 3.2% inhalation throughout the experiment. Chronic banding of the ascending aorta resulted in left ventricular hypertrophy development in two further groups and these animals underwent identical ischaemia,reperfusion protocols, with or without sevoflurane cardioprotection. Myocardial infarct sizes were compared post-mortem. Results: The mean myocardial infarct size (% of area-at-risk) was reduced from mean 55.0 (13.6%) (±SD) in controls to 17.5 (13.2%) by sevoflurane (P=0.001). Sevoflurane reduced the infarct size in hypertrophied hearts to 14.6 (10.4%) (P=0.001); however, in hypertrophic controls, infarcts were reduced to 34.2 (10.2%) (P=0.001). Conclusion: Sevoflurane abrogated ischaemic injury to similar levels in both normal and left ventricular hypertrophied hearts. [source]


    Proteomic analysis reveals protein changes within layer 2 of the insular cortex in schizophrenia

    PROTEINS: STRUCTURE, FUNCTION AND BIOINFORMATICS, Issue 23-24 2008
    Kyla Pennington
    Abstract Abnormalities in the size and activity of the insular cortex (IC), a brain region involved in auditory hallucinations and language, have been previously found in brain imaging studies in schizophrenia. In addition, cortical layer 2 has been shown to be abnormal in many brain regions in schizophrenia. In this study, 2-D DIGE was used to quantitatively analyse protein expression in schizophrenia and control cases (n,=,15/group) in microdissected layer 2 IC tissue. Proteomic analyses revealed 57 significantly differentially expressed (p<0.05) protein spots in schizophrenia. Validation of differential expression of two of the proteins differentially expressed was subsequently confirmed using Western blotting. This work provides evidence of abnormal protein expression in layer 2 of the IC in schizophrenia, supporting previous work of reduced neuronal size in this cortical layer in the IC. Over half of proteins abnormally expressed in this study have not been reported previously in proteomic studies investigating schizophrenia or neurodegenerative disorders. Proteins found to be abnormally expressed appear to collectively impact on neuronal plasticity through roles in neurite outgrowth, cellular morphogenesis and synaptic function. [source]


    Bacterial colonisation of root canal dentine previously treated with endodontic irrigants

    AUSTRALIAN ENDODONTIC JOURNAL, Issue 2 2010
    Brian J. Rasimick bs
    Abstract Certain irrigants leave antimicrobial residues on dentine. This study assessed if residues from MTAD, Endo-CHX, Peridex Oral Rinse or 6% NaOCl were inactivated by exposure to simulated leakage. Extracted teeth (15/group) were cut and drilled to produce a cylindrical canal space. They were irrigated, dried with paper points and transferred into 1 mL of simulated leakage (Enterococcus faecalis in tryptic soy broth) every 24 h. After one, two or three transfers, the number of colony forming units was measured by drilling the canal space and recovering the dentine shavings in antimicrobial-inactivating broth. Two-way anova of the log-transformed data showed irrigation method, leakage volume and their interaction were significant factors (P < 0.001). Compared with the positive control, the logarithmic reductions in the number of E. faecalis colonies after the first and third millilitre of leakage were: Endo-CHX 6.2 and 2.4; MTAD 3.4 and 2.7; Peridex 1.6 and 0.4; NaOCl 1.0 and 0.0. [source]


    Transplacental mutagenicity of N -ethyl- N -nitrosourea at the hprt locus in T-lymphocytes of exposed B6C3F1 mice

    ENVIRONMENTAL AND MOLECULAR MUTAGENESIS, Issue 1 2001
    Hillary E. Sussman
    Abstract Previous studies have compared age-related differences in total mutagenic burden in mice of differing age (preweanling, weanling, or young adult) after single intraperitoneal (i.p.) injections of ethylnitrosourea (ENU). The purpose of the present investigation was to determine the effects of time elapsed since treatment on the frequency of hprt mutant T-cells (Mf) from mice treated transplacentally with single acute vs. multiple split doses of ENU. To this end, pregnant C57BL/6 mice (n = 13,16/group), which had been bred to C3H males, were given i.p. injections of 40 mg ENU/kg bw in a single dose on day 18 of gestation, in a split dose of 6 mg ENU/kg bw on days 12 through 18 of gestation, or DMSO vehicle alone. Groups of pups were necropsied on days 10, 13, 15 (single dose only), 17, 20, 40, and 70 postpartum for T-cell isolations and hprt Mf measurements using the T-cell cloning assay. The time required to reach maximum Mfs in T-cells isolated from thymus of transplacentally treated animals was 2 weeks, the same time span as previously observed after ENU treatment of adult, weanling, and preweanling mice. Mfs in T-cells isolated from spleens of control animals averaged 2.1 ± 0.3 (SE) × 10,6. In spleens of mice treated transplacentally with ENU in a single dose, Mfs reached a maximum at 15 days postpartum [84.7 ± 15.8 (SE) × 10,6] and decreased to lower but still elevated levels at 40 days postpartum. In spleens of mice treated transplacentally with ENU in a split dose, Mfs reached a maximum at 13 days postpartum [74.0 ± 16.3 (SE) × 10,6] and decreased to background levels at 40 days postpartum. The areas under the curves describing the change in hprt Mfs over time for ENU-treated vs. control mice estimate the mutagenic potency for transplacental single- and split-dose exposures to be 1.9 and 0.8 × 103, respectively. Comparison of the mutagenic potency estimates for mice exposed to ENU in utero to 4-week-old mice given a similar dose of the same lot number of ENU indicates that the mouse is more susceptible to ENU-induced mutagenesis during fetal life. Environ. Mol. Mutagen. 38:30,37, 2001 © 2001 Wiley-Liss, Inc. [source]


    Immunological Response to (1,4)-,- d -Glucan in the Lung and Spleen of Endotoxin-Stimulated Juvenile Rats

    BASIC AND CLINICAL PHARMACOLOGY & TOXICOLOGY, Issue 5 2009
    Ectis A. Velazquez
    Experimental groups (n = 16/group) included controls with an intraperitoneal injection of saline, endotoxaemic rats with a non-lethal dose of 10 mg/kg Escherichia coli endotoxin, and endotoxaemic rats treated with two doses of 10 mg/kg ,-DG, intraperitoneally, 2 and 4 hr after endotoxin injection. At 24 hr of treatment, rats were euthanized and lungs and spleen were removed for cytokines determination and lung injury. Endotoxaemia increased IL-1, concentration by fivefold in both organs, while creating a moderate pulmonary hypercellularity (demonstrated by about 11% increase in the alveolar-septal thickening and 11% decrease in the alveolar-interstitial space ratio). In the lung, ,-DG treatment reduced concentrations of IL-1, by 30% (p > 0.05), IL-6 by 43% (p < 0.01), IFN-, by 46% (p < 0.01) and the anti-inflammatory cytokine, IL-10, by 31% (p > 0.05) compared to endotoxaemia. In the spleen, ,-DG treatment decreased the ratio of IL-1, to IL-10 by 55% (p < 0.05), demonstrating an anti-inflammatory trend. These data suggest that ,-DG differentially modulates cytokine response in the lung and spleen and modifies the pro- and anti-inflammatory balance during an early period of endotoxaemia in juvenile rats. [source]


    Impact of nutrition on outcome: A prospective randomized controlled trial in patients with head and neck cancer undergoing radiotherapy

    HEAD & NECK: JOURNAL FOR THE SCIENCES & SPECIALTIES OF THE HEAD AND NECK, Issue 8 2005
    Paula Ravasco MD
    Abstract Background. We aimed to determine the effect of dietary counseling or oral supplements on outcome for patients with cancer, specifically, nutritional outcome, morbidity, and quality of life (QOL), during and 3 months after radiotherapy. Methods. Seventy-five patients with head and neck cancer who were referred for radiotherapy (RT) were randomized to the following groups: group 1 (n = 25), patients who received dietary counseling with regular foods; group 2 (n = 25), patients who maintained usual diet plus supplements; and group 3 (n = 25), patients who maintained intake ad lib. Nutritional intake (determined by diet history) and status (determined by Ottery's Subjective Global Assessment), and QOL (determined by the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire version 3.0 [EORTC QLQ-C30]) were evaluated at baseline, at the end of RT, and at 3 months. Results. Energy intake after RT increased in both groups 1 and 2 (p , .05). Protein intake also increased in both groups 1 and 2 (p , .006). Both energy and protein intake decreased significantly in group 3 (p < .01). At 3 months, group 1 maintained intakes, whereas groups 2 and 3 returned to or below baseline levels. After RT, >90% of patients experienced RT toxicity; this was not significantly different between groups, with a trend for reduced symptomatology in group 1 versus group 2/group 3 (p < .07). At 3 months, the reduction of incidence/severity of grade 1+2 anorexia, nausea/vomiting, xerostomia, and dysgeusia was different: 90% of the patients improved in group 1 versus 67% in group 2 versus 51% in group 3 (p < .0001). After RT, QOL function scores improved (p < .003) proportionally with improved nutritional intake and status in group 1/group 2 (p < .05) and worsened in group 3 (p < .05); at 3 months, patients in group 1 maintained or improved overall QOL, whereas patients in groups 2 and 3 maintained or worsened overall QOL. Conclusions. During RT, nutritional interventions positively influenced outcomes, and counseling was of similar/higher benefit; in the medium term, only counseling exerted a significant impact on patient outcomes. © 2005 Wiley Periodicals, Inc. Head Neck27: XXX,XXX, 2005 [source]


    Alterations and reversibility in the chromatin, cytoskeleton and development of pig oocytes treated with roscovitine

    MOLECULAR REPRODUCTION & DEVELOPMENT, Issue 4 2003
    Jyh-Cherng Ju
    Abstract Germinal vesicle (GV) breakdown in mammalian oocytes is regulated by the activation of maturation promoting factor (MPF). We investigated a specific cdc2 kinase inhibitor, roscovitine, to maintain pig oocytes in the GV stage. Cumulus-oocyte complexes (COCs) were aspirated from slaughterhouse ovaries and cultured for 44 hr in NCSU#23 medium containing different levels of roscovitine (0, 10, 20, 30, 40, 50 ,M in Experiment 1 and 0, 40, 60, 80, 100, 120 ,M in Experiment 2). The COCs were cultured for another 44 hr after removal of the chemical. Twenty oocytes in each group were fixed at 44 hr for immunocytochemical labeling of the cytoskeleton and the rest (,20/group) were fixed at the end of 88 hr after culture. Results showed that the inhibition of the oocyte in the GV stage was not effective when 10,50 ,M (Experiment 1) of roscovitine were used (19,34%). When oocytes were released from the inhibitor, similar proportions (70,83%) of oocytes were observed in the MII or advanced stages among treatments. However, when higher concentrations of roscovitine were used (Experiment 2), significantly greater inhibitory effect was observed at the levels of 80,120 ,M with 83,91% oocytes being blocked in the GV stage when compared to the control (9%) and the 40,60 ,M (27,43%) groups (P,<,0.05). Although 15,21% of the oocytes showed abnormal MII morphology with aberrant meiotic spindles and/or formation of cytoplasmic microtubules, a substantial number of oocytes resumed meiosis and reached MII stage at 44 hr after removal of this chemical. In Experiment 3, different concentrations of roscovitine (0, 20, 40, and 80 ,M) were tested to examine the length of intervals (0, 11, 22, 33, and 44 hr) for an effective inhibition. Results showed that the inhibitory effect was significantly more prominent at 22 hr than that at 33 and 44 hr after roscovitine treatment in all treatment groups (P,<,0.05). This study demonstrated that roscovitine-treated oocytes resumed meiosis after removal of the inhibitor. This could provide flexibility for studying porcine oocyte development and embryo cloning and may have application in other species. Mol. Reprod. Dev. 64: 482,491, 2003. © 2003 Wiley-Liss, Inc. [source]


    Lack of adverse effects in pregnant/lactating female rats and their offspring following pre- and postnatal exposure to ELF magnetic fields

    BIOELECTROMAGNETICS, Issue 4 2004
    Moon-Koo Chung
    Abstract We have recently reported that exposure of pregnant rats to 60 Hz at field strengths up to 0.5 mT during the entire period of pregnancy did not induce any biologically significant effects on both pregnant dams and embryo-fetal development. The present study was carried out to investigate the potential effects of gestational and lactational MF exposure on pregnancy, delivery, and lactation of dams and growth, behavior, and mating performance of their offspring in rats. Timed-pregnant female Sprague,Dawley (SD) rats (24/group) received continuous exposure to 60 Hz magnetic field (MF) at field strengths of 0 (sham control), 5 ,T, 83.3 ,T, or 0.5 mT. Dams received MF or sham exposures for 21 h/day from gestational day 6 through lactational day 21. Experimentally generated MF was monitored continuously throughout the study. No exposure-related changes in clinical signs, body weight, food consumption, pregnancy length, and necropsy findings were observed in dams. Parameters of growth, behavior, and reproductive performance of offspring showed no changes related to MF exposure. There were no adverse effects on embryo-fetal development of F2 offspring from dams exposed to MF. In conclusion, exposure of pregnant SD rats to 60 Hz at field strengths up to 0.5 mT from gestational day 6 to lactational day 21 did not produce biologically significant effects in dams, F1 offspring, or F2 fetuses. Bioelectromagnetics 25:236,244, 2004. © 2004 Wiley-Liss, Inc. [source]


    Developmental toxicity evaluation of ELF magnetic fields in Sprague,Dawley rats

    BIOELECTROMAGNETICS, Issue 4 2003
    Moon-Koo Chung
    Abstract To identify possible effects of horizontally polarized magnetic field (MF) exposure on maintenance of pregnancy and embryo-fetal development, an MF exposure system was designed and constructed and 96 time-mated female Sprague,Dawley (SD) rats (24/group) received continuous exposure to 60 Hz MF at field strengths of 0 (sham control) and 5, 83.3, or 500 ,T (50, 833, or 5000 mG). Dams received MF or sham exposures for 22 h/day on gestational day 6,20. MF was monitored continuously throughout the study. There were no evidences of maternal toxicity or developmental toxicity in any MF exposed groups. Mean maternal body weight, organ weights, and hematological and serum biochemical parameters in groups exposed to MF did not differ from those in sham control. No exposure related differences in fetal deaths, fetal body weight, and placental weight were observed between MF exposed groups and sham control. External, visceral, and skeletal examination of fetuses demonstrated no significant differences in the incidence of fetal malformations between MF exposed and sham control groups. In conclusion, exposure of pregnant rats to 60 Hz at MF strengths up to 500 ,T during gestation day 6,20 did not produce any biologically significant effect in either dams or fetuses. Bioelectromagnetics 24:231-240, 2003. © 2003 Wiley-Liss, Inc. [source]


    A Mouse Model of Hypercholesterolemia-Induced Erectile Dysfunction

    THE JOURNAL OF SEXUAL MEDICINE, Issue 4i 2007
    Donghua Xie MD
    ABSTRACT Introduction., Hypercholesterolemia is one of the most important risk factors for the development of erectile dysfunction (ED) in men. Aim., We employed an established mouse model of hypercholesterolemia. Main Outcome Measures., We test for abnormalities in vasoreactivity in corporal tissue and temporally correlated changes in vasoreactivity with alterations in histology and protein expression. Methods., A total of 150 mice were studied. A total of 100 apolipoprotein-E knockout (ApoE,/,) mice were fed a 1.25% cholesterol diet for 2, 4, 8, and 12 weeks (N = 25/group), while a group of ApoE,/, and wild-type Bl-6 mice were fed a normal diet. The study was terminated, and all mice were harvested at 22 weeks of age for vasoreactivity, histology, and protein studies from corporal tissues. Dose,response curves were generated to evaluate endothelium-dependent and endothelium-independent vasoreactivity, ex vivo. The contents of endothelial cells, smooth muscle cells, and smooth muscle/collagen ratio were assessed by immunohistochemistry staining or Masson staining. Level of cyclic guanosine monophosphate (cGMP) was detected by enzyme immunoassay assay. Levels of phosphorylated endothelial nitric oxide synthase (p-eNOS)/total eNOS, neuronal nitric oxide synthase (nNOS), and cyclic GMP-dependent kinase (cGK-1) protein were assessed by Western analysis. Results., Abnormalities in endothelium-dependent and endothelium-independent vasoreactivities, endothelial content, smooth muscle/collagen ratio, p-eNOS phosphorylation at Ser1177 only, nNOS, cGMP, and cGK-1 changed with the different durations of the high-cholesterol diet. Conclusions., These data demonstrate that this mouse model is suitable for investigating aspects of hypercholesterolemic ED. Xie D, Odronic SI, Wu F, Pippen AM, Donatucci CF, and Annex BH. A mouse model of hypercholesterolemia-induced erectile dysfunction. J Sex Med 2007;4:898,907. [source]


    Down-regulation of neurocan expression in reactive astrocytes promotes axonal regeneration and facilitates the neurorestorative effects of bone marrow stromal cells in the ischemic rat brain

    GLIA, Issue 16 2008
    Li Hong Shen
    Abstract The glial scar, a primarily astrocytic structure bordering the infarct tissue inhibits axonal regeneration after stroke. Neurocan, an axonal extension inhibitory molecule, is up-regulated in the scar region after stroke. Bone marrow stromal cells (BMSCs) reduce the thickness of glial scar wall and facilitate axonal remodeling in the ischemic boundary zone. To further clarify the role of BMSCs in axonal regeneration and its underlying mechanism, the current study focused on the effect of BMSCs on neurocan expression in the ischemic brain. Thirty-one adult male Wistar rats were subjected to 2 h of middle cerebral artery occlusion followed by an injection of 3 × 106 rat BMSCs (n = 16) or phosphate-buffered saline (n = 15) into the tail vein 24 h later. Animals were sacrificed at 8 days after stroke. Immunostaining analysis showed that reactive astrocytes were the primary source of neurocan, and BMSC-treated animals had significantly lower neurocan and higher growth associated protein 43 expression in the penumbral region compared with control rats, which was confirmed by Western blot analysis of the brain tissue. To further investigate the effects of BMSCs on astrocyte neurocan expression, single reactive astrocytes were collected from the ischemic boundary zone using laser capture microdissection. Neurocan gene expression was significantly down-regulated in rats receiving BMSC transplantation (n = 4/group). Primary cultured astrocytes showed similar alterations; BMSC coculture during reoxygenation abolished the up-regulation of neurocan gene in astrocytes undergoing oxygen-glucose deprivation (n = 3/group). Our data suggest that BMSCs promote axonal regeneration by reducing neurocan expression in peri-infarct astrocytes. © 2008 Wiley-Liss, Inc. [source]


    Influence of general anaesthesia on the pharmacokinetics of intravenous fentanyl and its primary metabolite in horses

    EQUINE VETERINARY JOURNAL, Issue 1 2007
    S. M. THOMASY
    Summary Reasons for performing study: In order to evaluate its potential as an adjunct to inhalant anaesthesia in horses, the pharmacokinetics of fentanyl must first be determined. Objectives: To describe the pharmacokinetics of fentanyl and its metabolite, N-[1-(2-phenethyl-4-piperidinyl)maloanilinic acid (PMA), after i.v. administration of a single dose to horses that were awake in Treatment 1 and anaesthetised with isoflurane in Treatment 2. Methods: A balanced crossover design was used (n = 4/group). During Treatment 1, horses received a single dose of fentanyl (4 ,g/kg bwt, i.v.) and during Treatment 2, they were anaesthetised with isoflurane and maintained at 1.2 × minimum alveolar anaesthetic concentration. After a 30 min equilibration period, a single dose of fentanyl (4 ,g/kg bwt, i.v.) was administered to each horse. Plasma fentanyl and PMA concentrations were measured at various time points using liquid chromatography-mass spectrometry. Results: Anaesthesia with isoflurane significantly decreased mean fentanyl clearance (P < 0.05). The fentanyl elimination half-life, in awake and anaesthetised horses, was 1 h and volume of distribution at steady state was 0.37 and 0.26 l/kg bwt, respectively. Anaesthesia with isoflurane also significantly decreased PMA apparent clearance and volume of distribution. The elimination half-life of PMA was 2 and 1.5 h in awake and anaesthetised horses, respectively. Conclusions and potential relevance: Pharmacokinetics of fentanyl and PMA in horses were substantially altered in horses anaesthetised with isoflurane. These pharmacokinetic parameters provide information necessary for determination of suitable fentanyl loading and infusion doses in awake and isoflurane-anaesthetised horses. [source]


    Down-regulation of neurocan expression in reactive astrocytes promotes axonal regeneration and facilitates the neurorestorative effects of bone marrow stromal cells in the ischemic rat brain

    GLIA, Issue 16 2008
    Li Hong Shen
    Abstract The glial scar, a primarily astrocytic structure bordering the infarct tissue inhibits axonal regeneration after stroke. Neurocan, an axonal extension inhibitory molecule, is up-regulated in the scar region after stroke. Bone marrow stromal cells (BMSCs) reduce the thickness of glial scar wall and facilitate axonal remodeling in the ischemic boundary zone. To further clarify the role of BMSCs in axonal regeneration and its underlying mechanism, the current study focused on the effect of BMSCs on neurocan expression in the ischemic brain. Thirty-one adult male Wistar rats were subjected to 2 h of middle cerebral artery occlusion followed by an injection of 3 × 106 rat BMSCs (n = 16) or phosphate-buffered saline (n = 15) into the tail vein 24 h later. Animals were sacrificed at 8 days after stroke. Immunostaining analysis showed that reactive astrocytes were the primary source of neurocan, and BMSC-treated animals had significantly lower neurocan and higher growth associated protein 43 expression in the penumbral region compared with control rats, which was confirmed by Western blot analysis of the brain tissue. To further investigate the effects of BMSCs on astrocyte neurocan expression, single reactive astrocytes were collected from the ischemic boundary zone using laser capture microdissection. Neurocan gene expression was significantly down-regulated in rats receiving BMSC transplantation (n = 4/group). Primary cultured astrocytes showed similar alterations; BMSC coculture during reoxygenation abolished the up-regulation of neurocan gene in astrocytes undergoing oxygen-glucose deprivation (n = 3/group). Our data suggest that BMSCs promote axonal regeneration by reducing neurocan expression in peri-infarct astrocytes. © 2008 Wiley-Liss, Inc. [source]


    Tissue edema does not change gadolinium-diethylenetriamine pentaacetic acid (Gd-DTPA)-enhanced T1 relaxation times of viable myocardium,,

    JOURNAL OF MAGNETIC RESONANCE IMAGING, Issue 6 2005
    Gang Li MD
    Abstract Purpose To determine whether tissue edema changes gadolinium-diethylenetriamine pentaacetic acid (Gd-DTPA)-enhanced T1 relaxation times of the viable myocardium. Materials and Methods A total of 16 isolated pig hearts were divided into four groups (N = 4/group) and perfused in a Langendorff apparatus. Gd-DTPA was injected into the aortic perfusion line. Tissue edema was then induced by two hours of simultaneous arterial/venous perfusion (SAVP). Myocardial water content and T1 relaxation times were monitored throughout SAVP. The volumes of the extracellular and intracellular compartments were assessed using 31P MRS-detectable markers, phenylphosphonic acid (PPA) and dimethyl methylphosphonate (DMMP). Results Tissue water content in both viable and infarcted myocardium increased significantly during two-hour SAVP. However, Gd-DTPA-enhanced T1 relaxation times of the viable myocardium remained relatively unchanged. Infarcted myocardium, on the other hand, exhibited significant T1 shortening during SAVP. Furthermore, SAVP resulted in significant expansions of both extracellular and intracellular compartments, but the ratio of the volumes of the two compartments remained relatively constant. Conclusion Tissue edema in the viable myocardium does not increase the relative distribution volume of the contrast agent. As a result, edema does not change Gd-DTPA-enhanced T1 relaxation times of the viable myocardium. J. Magn. Reson. Imaging 2005;21:744,751. Published 2005 Wiley-Liss, Inc. [source]


    Changes in Expression of the Genes for the Leptin Receptor and the Growth Hormone-Releasing Peptide/Ghrelin Receptor in the Hypothalamic Arcuate Nucleus with Long-Term Manipulation of Adiposity by Dietary Means

    JOURNAL OF NEUROENDOCRINOLOGY, Issue 6 2005
    Y. Kurose
    Abstract Changes in leptin and ghrelin levels occur with alterations in adiposity, but signalling may be affected by levels of the relevant receptors. We measured expression of the leptin receptor (Ob-Rb) and the ghrelin/growth hormone releasing peptide receptor (GHS-R) in the arcuate nucleus of sheep held at either high or low levels of adiposity. Plasma growth hormone (GH) levels were lower in Fat animals and higher in Lean animals. Plasma insulin and leptin levels were higher in Fat animals and lower in Lean animals. Frozen hypothalamic sections of arcuate nucleus were extracted and mRNA levels measured for mRNA for Ob-Rb and GHS-R. Gene expression for both Ob-Rb and GHS-R was higher in Lean animals than in Fat animals, with no difference in expression between Fat and Normal animals. A second group of animals (n = 4 per group) was used for double-labelling immunohistochemistry to determine whether the increase in Ob-Rb gene expression was translated into Ob-Rb protein and to ascertain whether this effect is localised to the cells of the arcuate nucleus that produce either neuropeptide Y (NPY) and/or pro-opiomelanocortin-derived peptides. Lean animals displayed a 255% increase in immunoreactive NPY cells (P < 0.005), a 167% increase in cells with Ob-Rb (P < 0.037) protein and a 344% increase in cells that were staining for both NPY and Ob-Rb (P < 0.02). There was no difference between the Normal and Lean animals in the number of cells that were detected with an adrenocorticotrophic hormone (ACTH) antibody or the number of ACTH-immunoreactive cells that also stained for Ob-Rb. Finally, we measured plasma ghrelin levels in Normal, Fat and Lean ewes (n = 4/group); levels were higher (P < 0.05) in Fat animals than in Lean animals. We conclude that lowering body weight leads to increased expression of Ob-Rb, ghrelin/GHS-R expression and proportion of NPY cells that express Ob-Rb in the arcuate nucleus. This may be an adaptive mechanism to increase responsivity to both leptin and ghrelin. [source]


    Changes in mean arterial pressure predict degranulation of renomedullary interstitial cells

    CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, Issue 12 2002
    Christine Maric
    Summary 1.,Renomedullary interstitial cells (RMIC) are characterized by numerous intracellular granules thought to contain renal medullary antihypertensive substances. However, the nature of the trigger for RMIC degranulation remains to be elucidated. The present study examines the effects of acute alterations in mean arterial pressure (MAP) and medullary blood flow (MBF) on RMIC granulation. 2.,Basal MAP and MBF in anaesthetized Sprague-Dawley rats (n = 4/group) were altered by intravenous infusions of vasoactive agents, including angiotensin II alone or with a nitric oxide (NO) synthase inhibitor (N, -nitro- l -arginine) or NO donor (sodium nitroprusside), noradrenaline and by carotid artery clamping. Following these treatments, kidneys were examined by electron microscopy and the absolute volume of granules in the renal medulla was calculated using unbiased stereological methods. 3.,Acute increases in MAP, regardless of the treatment causing the increase, were associated with a reduction in the absolute volume of granules in the range of 42,67%. Regression analysis revealed that only increases in MAP, but not MBF, strongly predict RMIC degranulation. 4.,Despite previous reports that changes in MBF activate renomedullary antihypertensive activity, we conclude that the change in MAP is an important determinant of the activity of the blood pressure-lowering mechanism of the renal medulla, with the assumption that the medullary lipids mediate the antihypertensive property of the renal medulla. [source]


    Effects of a MAPK p38 inhibitor on lung function and airway inflammation in equine recurrent airway obstruction

    EQUINE VETERINARY JOURNAL, Issue 6 2008
    J.-P. LAVOIE
    Summary Reasons for performing study: It has been suggested that many of the beneficial effects of corticosteroids are mediated through mitogen-activated protein kinase (MAPK) p38 inhibition. Objective: To investigate the efficacy of the MAPK p38 inhibitor compound MRL-EQ1 to either prevent (Phase 1) or treat (Phase 2) recurrent airway obstruction (RAO) in horses. Methods: MRL-EQ1 was administered i.v. at a dosage of 0.75-1.5 mg/kg bwt q. 12 h. In Phase 1, susceptible horses in clinical remission were divided into 2 groups (n = 5/group), based on historical values of respiratory mechanics. All horses were entered in the study in pairs (one control, one treated horse) and exposed to the same environmental challenge (stabling, mouldy hay and dusty conditions). The treatment group received MRL-EQ1 for 14 days while the control horses were untreated during the same period. In Phase 2, affected horses were ranked by severity of respiratory dysfunction and split randomly into either dexamethasone or MRL-EQ1 treatment groups (n = 5/group). Bronchoalveolar lavage fluid, respiratory mechanic measurements, MRL-EQ1 plasma concentration and tumour necrosis factor (TNF) whole blood activity were evaluated sequentially. Results: In Phase 1, MRL-EQ1 did not prevent the occurrence of clinical signs and pulmonary inflammation. However, treatment was associated with a reduction in severity and a delay in the onset of signs and a reduction in pulmonary neutrophilia. In Phase 2, plasma concentrations achieved resulted in ex vivo suppression of lipopolysaccharide-induced TNF production in equine blood. MRL-EQ1 did not improve airway inflammation or lung function and was associated in a dose dependent manner with behavioural (depression, excitability) and blood changes (neutrophilia, increased serum muscle enzyme concentrations). Conclusions: Inhibition of p38 in the horse was partially effective in reducing clinical signs and airway inflammation when administered prior to, but not during clinical exacerbation in RAO. Potential relevance: Inhibitors of p38 MAPK with a better toxicity profile may be effective in the prevention or treatment of RAO. [source]


    Recovery of Trabecular and Cortical Bone Turnover After Discontinuation of Risedronate and Alendronate Therapy in Ovariectomized Rats

    JOURNAL OF BONE AND MINERAL RESEARCH, Issue 10 2008
    Robyn K Fuchs
    Abstract Alendronate (ALN) and risedronate (RIS) are bisphosphonates effective in reducing bone loss and fractures associated with postmenopausal osteoporosis. However, it is uncertain how long it takes bone turnover to be re-established after treatment withdrawal, and whether this differs between the two drugs. The objective of this study was to determine the time required to re-establish normal bone turnover after the discontinuation of ALN and RIS treatment in an animal model of estrogen-deficiency osteoporosis. Two hundred ten, 6-mo-old female Sprague-Dawley rats were ovariectomized and 6 wk later were randomized into baseline controls (n = 10) and four treatment groups (n = 50/group): vehicle-treated controls (CON; 0.3 ml sterile water), ALN (2.4 ,g/kg), low-dose RIS (RIS low; 1.2 ,g/kg), and high-dose RIS (RIS high; 2.4 ,g/kg). Treatments were administered 3 times/wk by subcutaneous injection. Baseline controls were killed at the initiation of treatment. Other groups were treated for 8 wk, and subgroups (n = 10/ treatment group) were killed 0, 4, 8, 12, and 16 wk after treatment was withdrawn. Static and dynamic histological analyses were performed for cortical (tibial diaphysis) and trabecular (proximal tibia and L4 vertebrae) bone. DXA and mechanical testing was performed on the L5 vertebra. After 8 wk of treatment, trabecular bone turnover rates were significantly suppressed in all drug-treated animals. Trabecular bone formation rate (BFR/BS) remained significantly lower than vehicle in bisphosphonate-treated animals through 12 wk. Sixteen weeks after treatment withdrawal, trabecular BFR/BS in the proximal tibia was re-established in animals treated with RIS but not in animals treated with ALN compared with controls. BMD of the fifth lumbar vertebra remained significantly higher than controls 16 wk after treatment withdrawal in ALN-treated animals but not in RIS-treated animals. Despite reductions in BMD and increases in bone turnover, ultimate force of the fifth lumbar vertebra remained significantly higher in all drug-treated animals through 16 wk after withdrawal. [source]


    Physical activity reduces prostate carcinogenesis in a transgenic model

    THE PROSTATE, Issue 13 2009
    Karyn A. Esser
    Abstract BACKGROUND Several epidemiological studies have reported an inverse association between physical activity and the risk of prostate cancer. To date, there are few animal studies looking at physical activity and cancer incidence, although the results are consistent with the epidemiological evidence. In general, as exercise intensity increased in the rats/mice, the likelihood that physical activity inhibited carcinogenesis increased. METHODS The present study used voluntary wheel running with C3(1)Tag mice that are predisposed to prostate cancer due to the directed expression of SV40 oncogenes. After 10 weeks, the prostates were collected from run and non-run mice and histopathology performed for the presence or absence of low grade or high grade PINS. RESULTS We found that for those mice that ran >5Km/group, 83% of the dorsolateral prostates were classified as within normal levels vs. 43% for the <5 km/day group (p,=,0.16). In addition, there was a relationship between average distance run and pathologic progression to high-grade PIN and local invasion, considered to be an early event in the formation of prostate adenocarcinoma. Forty three percent of dorsalateral prostates from mice that ran less than 5 km/day were classified with advanced pathology as compared to none (0) in mice that ran more than 5.0 km/day (p,=,0.05). CONCLUSIONS The results presented herein indicate that prostatic cancer progression is likely delayed or diminished by wheel running activity in a dose dependent manner in transgenic mice. These findings provide further evidence that exercise acts to decrease the progression of prostate cancer and they establish a transgenic animal model for future studies to define mechanism(s). Prostate 69: 1372,1377, 2009. © 2009 Wiley-Liss, Inc. [source]


    Ovariectomy-Induced Bone Loss Varies Among Inbred Strains of Mice,

    JOURNAL OF BONE AND MINERAL RESEARCH, Issue 7 2005
    Mary L Bouxsein PhD
    Abstract There is a subset of women who experience particularly rapid bone loss during and after the menopause. However, the factors that lead to this enhanced bone loss remain obscure. We show that patterns of bone loss after ovariectomy vary among inbred strains of mice, providing evidence that there may be genetic regulation of bone loss induced by estrogen deficiency. Introduction: Both low BMD and increased rate of bone loss are risk factors for fracture. Bone loss during and after the menopause is influenced by multiple hormonal factors. However, specific determinants of the rate of bone loss are poorly understood, although it has been suggested that genetic factors may play a role. We tested whether genetic factors may modulate bone loss subsequent to estrogen deficiency by comparing the skeletal response to ovariectomy in inbred strains of mice. Materials and Methods: Four-month-old mice from five inbred mouse strains (C3H/HeJ, BALB/cByJ, CAST/EiJ, DBA2/J, and C57BL/6J) underwent ovariectomy (OVX) or sham-OVX surgery (n = 6-9/group). After 1 month, mice were killed, and ,CT was used to compare cortical and trabecular bone response to OVX. Results: The effect of OVX on trabecular bone varied with mouse strain and skeletal site. Vertebral trabecular bone volume (BV/TV) declined after OVX in all strains (,15 to ,24%), except for C3H/HeJ. In contrast, at the proximal tibia, C3H/HeJ mice had a greater decline in trabecular BV/TV (,39%) than C57BL/6J (,18%), DBA2/J (,23%), and CAST/EiJ mice (,21%). OVX induced declines in cortical bone properties, but in contrast to trabecular bone, the effect of OVX did not vary by mouse strain. The extent of trabecular bone loss was greatest in those mice with highest trabecular BV/TV at baseline, whereas cortical bone loss was lowest among those with high cortical bone parameters at baseline. Conclusions: We found that the skeletal response to OVX varies in a site- and compartment-specific fashion among inbred mouse strains, providing support for the hypothesis that bone loss during and after the menopause is partly genetically regulated. [source]


    Effect of vascular injury on inhibition of venous thrombosis with ZK-807834, a direct inhibitor of factor Xa

    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, Issue 9 2003
    D. R. Abendschein
    Summary., Inhibition of factor Xa with the small molecule inhibitor ZK-807834 (Mr 527 Da, Ki 0.11 nM) attenuates progression of thrombosis, but the ED50 is substantially lower for venous compared with arterial thrombosis in experimental animals. To determine whether this reflects differences in the extent of vascular injury, we compared the dose,response of ZK-807834 for inhibition of venous thrombosis induced with a cotton thread and copper wire device in the presence and absence of balloon catheter-induced injury to the vena cava in rabbits. ZK-807834 administration over 2 h (total dosages of 0.0023,2.3 µmol kg,1, n = 6/group) resulted in dose-dependent reductions in clot weight compared with vehicle controls, but the ED50 was 0.03 µmol kg,1 for non-injured veins and 0.42 µmol kg,1 for injured veins. We conclude that vascular injury invokes a tissue factor-mediated response that increases the dose requirements for inhibition of venous thrombosis with ZK-807834. [source]


    ,-Arrestin2 Regulates the Differential Response of Cortical and Trabecular Bone to Intermittent PTH in Female Mice,

    JOURNAL OF BONE AND MINERAL RESEARCH, Issue 4 2005
    Mary L Bouxsein PhD
    Abstract Cytoplasmic arrestins regulate PTH signaling in vitro. We show that female ,-arrestin2,/, mice have decreased bone mass and altered bone architecture. The effects of intermittent PTH administration on bone microarchitecture differed in ,-arrestin2,/, and wildtype mice. These data indicate that arrestin-mediated regulation of intracellular signaling contributes to the differential effects of PTH at endosteal and periosteal bone surfaces. Introduction: The effects of PTH differ at endosteal and periosteal surfaces, suggesting that PTH activity in these compartments may depend on some yet unidentified mechanism(s) of regulation. The action of PTH in bone is mediated primarily by intracellular cAMP, and the cytoplasmic molecule ,-arrestin2 plays a central role in this signaling regulation. Thus, we hypothesized that arrestins would modulate the effects of PTH on bone in vivo. Materials and Methods: We used pDXA, ,CT, histomorphometry, and serum markers of bone turnover to assess the skeletal response to intermittent PTH (0, 20, 40, or 80 ,g/kg/day) in adult female mice null for ,-arrestin2 (,-arr2,/,) and wildtype (WT) littermates (7-11/group). Results and Conclusions: ,-arr2,/, mice had significantly lower total body BMD, trabecular bone volume fraction (BV/TV), and femoral cross-sectional area compared with WT. In WT females, PTH increased total body BMD, trabecular bone parameters, and cortical thickness, with a trend toward decreased midfemoral medullary area. In ,-arr2,/, mice, PTH not only improved total body BMD, trabecular bone architecture, and cortical thickness, but also dose-dependently increased femoral cross-sectional area and medullary area. Histomorphometry showed that PTH-stimulated periosteal bone formation was 2-fold higher in ,-arr2,/, compared with WT. Osteocalcin levels were significantly lower in ,-arr2,/, mice, but increased dose-dependently with PTH in both ,-arr2,/, and WT. In contrast, whereas the resorption marker TRACP5B increased dose-dependently in WT, 20-80 ,g/kg/day of PTH was equipotent with regard to stimulation of TRACP5B in ,-arr2,/,. In summary, ,-arrestin2 plays an important role in bone mass acquisition and remodeling. In estrogen-replete female mice, the ability of intermittent PTH to stimulate periosteal bone apposition and endosteal resorption is inhibited by arrestins. We therefore infer that arrestin-mediated regulation of intracellular signaling contributes to the differential effects of PTH on cancellous and cortical bone. [source]